Request Demo
Last update 25 Feb 2026
Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)
Last update 25 Feb 2026
Overview
Basic Info
Drug Type TIL therapy |
Synonyms TILS Shanghai Gencells Therapeutics, Tumor infiltrating lymphocytes Shanghai Gencells Therapeutics |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
8
Clinical Trials associated with Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)NCT05087745
A Clinical Study on Tumor Infiltrating Lymphocytes for the Treatment of Advanced Solid Tumors
NCT05142475
A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Breast Cancer
NCT05098184
A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Melanoma
100 Clinical Results associated with Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)
Login to view more data
100 Translational Medicine associated with Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)
Login to view more data
100 Patents (Medical) associated with Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)
Login to view more data
100 Deals associated with Autologous tumour infiltrating lymphocytes (Shanghai Gencells Therapeutics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 12 Oct 2022 | |
| Advanced breast cancer | Phase 1 | China | 19 Nov 2021 | |
| Liver Cancer | Phase 1 | China | 26 Sep 2021 | |
| Melanoma | Phase 1 | China | 26 Sep 2021 | |
| Gastrointestinal Stromal Tumors | Phase 1 | China | 27 Jun 2021 | |
| Malignant glioma of brain | Phase 1 | China | 06 May 2021 | |
| Glioma | Phase 1 | China | 14 Apr 2021 | |
| Female Genital Neoplasms | Phase 1 | China | 04 Jan 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04766320 (Pubmed) Manual  | Phase 1 | 14 | eqccrlvzpo(frojduwlia) = In the clinical section, all enrolled patients received TIL infusion using a modified TIL therapy regimen successfully with a manageable safety profile. remhbzgevd (rkjmubjawo ) View more | Positive | 20 May 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free